Childhood brain tumors: current management, biological insights, and future directions: JNSPG 75th Anniversary Invited Review Article

IF Pollack, S Agnihotri, A Broniscer - Journal of Neurosurgery: Pediatrics, 2019 - thejns.org
Brain tumors are the most common solid tumors in children, and, unfortunately, many
subtypes continue to have a suboptimal long-term outcome. During the last several years …

Medulloblastoma

PA Northcott, GW Robinson, CP Kratz… - Nature reviews Disease …, 2019 - nature.com
Medulloblastoma (MB) comprises a biologically heterogeneous group of embryonal tumours
of the cerebellum. Four subgroups of MB have been described (WNT, sonic hedgehog …

The whole-genome landscape of medulloblastoma subtypes

PA Northcott, I Buchhalter, AS Morrissy, V Hovestadt… - Nature, 2017 - nature.com
Current therapies for medulloblastoma, a highly malignant childhood brain tumour, impose
debilitating effects on the develo** child, and highlight the need for molecularly targeted …

Resolving medulloblastoma cellular architecture by single-cell genomics

V Hovestadt, KS Smith, L Bihannic, MG Filbin… - Nature, 2019 - nature.com
Medulloblastoma is a malignant childhood cerebellar tumour type that comprises distinct
molecular subgroups. Whereas genomic characteristics of these subgroups are well …

Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study

EC Schwalbe, JC Lindsey, S Nakjang, S Crosier… - The Lancet …, 2017 - thelancet.com
Background International consensus recognises four medulloblastoma molecular
subgroups: WNT (MB WNT), SHH (MB SHH), group 3 (MB Grp3), and group 4 (MB Grp4) …

Risk stratification of childhood medulloblastoma in the molecular era: the current consensus

V Ramaswamy, M Remke, E Bouffet, S Bailey… - Acta …, 2016 - Springer
Historical risk stratification criteria for medulloblastoma rely primarily on clinicopathological
variables pertaining to age, presence of metastases, extent of resection, histological …

Medulloblastomics revisited: biological and clinical insights from thousands of patients

V Hovestadt, O Ayrault, FJ Swartling… - Nature Reviews …, 2020 - nature.com
Medulloblastoma, a malignant brain tumour primarily diagnosed during childhood, has
recently been the focus of intensive molecular profiling efforts, profoundly advancing our …

Outcomes by clinical and molecular features in children with medulloblastoma treated with risk-adapted therapy: results of an international phase III trial (SJMB03)

A Gajjar, GW Robinson, KS Smith, T Lin… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE SJMB03 (ClinicalTrials. gov identifier: NCT00085202) was a phase III risk-
adapted trial that aimed to determine the frequency and clinical significance of biological …

Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis

EM Thompson, T Hielscher, E Bouffet, M Remke… - The lancet …, 2016 - thelancet.com
Background Patients with incomplete surgical resection of medulloblastoma are
controversially regarded as having a marker of high-risk disease, which leads to patients …

Vismodegib exerts targeted efficacy against recurrent sonic hedgehog–subgroup medulloblastoma: results from phase II pediatric brain tumor consortium studies …

GW Robinson, BA Orr, G Wu, S Gururangan… - Journal of Clinical …, 2015 - ascopubs.org
Purpose Two phase II studies assessed the efficacy of vismodegib, a sonic hedgehog (SHH)
pathway inhibitor that binds smoothened (SMO), in pediatric and adult recurrent …